AlphAIAlphAI — Financial news for AI agents
investing.com$MYGN

Myriad Genetics earnings beat by $0.09, revenue topped estimates

Myriad Genetics (MYGN) reported Q1 EPS of -$0.11, beating estimates by $0.09, with revenue of $202.7M, exceeding expectations of $191.33M. The stock is up 84.66% over 3 months but down 4.90% year-over-year. InvestingPro rates its financial health as 'good performance'.

Original reporting
investing.com
Published Nov 5, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MYGN
Bullish
high confidence
Mentioned
$MYGN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MYGNBullishMed
01

Why it matters

The earnings surprise could prompt short-term buying, but the company remains loss-making.

02

Market read

Earnings beat may provide a short-term catalyst for MYGN and related biotech stocks.

03

What to watch

Potential concerns about ongoing losses and cash burn not addressed in the brief.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Myriad Genetics (NASDAQ: MYGN) posted its first quarter results, surpassing analyst expectations on earnings and revenue.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Myriad Genetics reported Q1 EPS of -$0.11, beating estimates by $0.09 and revenue of $202.7M vs $191.33M consensus.

Expected impact

likely upward pressure as investors price in the earnings beat

Evidence & confidence

Beat on both EPS and revenue typically drives short-term buying interest.

Market effects

Sector

May lift other genetics and biotech stocks as earnings beat signals sector resilience.

Regional

Limited to US biotech market.

Global

Low global impact.

Counterpoint

What could challenge this read

The beat may be modest and could be priced in quickly, limiting upside.

Key entities

  • company
    Myriad Genetics

    Genetic testing and diagnostics firm.

Read at source← All news

StoryMyriad Genetics posts Q3 earnings beat and lifts full‑year revenue outlook

Also covered by

1 outlet

Related articles

$MYGNMed

Myriad Genetics Q3 Earnings Call Highlights

Myriad Genetics (NASDAQ:MYGN) expects revenue growth and gross margin improvements post-divestiture. Q3 revenue rose 1% to $124M, with hereditary cancer test volume up 6%. The company raised 2026 revenue guidance to $780M-$790M. GeneSight test revenue increased 2% to $40M. Myriad plans to manage Precise MRD test demand until reimbursement begins in 2027 and is pursuing cost-cutting initiatives.

finance.yahoo.com
$MYGNHighAI 8/10

Myriad Genetics Reports Third Quarter 2026 Financial Results

MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives Highl ights • Third quarter 2026

SEC EDGAR 8-K
$LHHighAI 9/10

Labcorp adds more diagnostic services

Labcorp announced acquisitions totaling over $1 billion, including BioReference Health for up to $872 million and Myriad Genetics' Prenatal Health business for $210 million. The deals are expected to add $410 million in first-year revenue. Labcorp aims to expand diagnostic services, while Opko Health will focus on biopharmaceuticals.

thetimesnews.com
$MYGNMedAI 8/10

Myriad Genetics presents data on cancer recurrence detection test

Myriad Genetics (NASDAQ:MYGN) presented data from the MONSTAR-SCREEN-3 study on its Precise MRD platform, showing it can detect molecular residual disease in colorectal and pancreatic cancer patients post-surgery, with early detection of recurrence. The study will be presented at the European Society for Medical Oncology Congress 2026. The company claims the platform offers personalized monitoring for recurrence risk.

investing.com